Skip to main content

BLUE

Stock

BLUE

Stock
Health Care
Biotechnology

Performance overview

BLUE Price
Price Chart

Forward-looking statistics

Beta
2.26
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Company info

SectorHealth Care
IndustryBiotechnology
Employees528
Market cap$174.4M

Fundamentals

Enterprise value$5.0M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.03
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$3K
Avg trading volume (10 day)$1K
Put-call ratio

Macro factor sensitivity

Growth+1.6
Credit+9.7
Liquidity+1.2
Inflation-5.4
Commodities-1.9
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-0.04
Price to sales
P/E Ratio-7.65
Enterprise Value to Revenue
Price to book-32.08

Upcoming events

Next earnings day
Next dividend day
Ex. dividend day

News

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Bluebird Bio (BLUE) came out with a quarterly loss of $2.66 per share versus the Zacks Consensus Estimate of a loss of $3.60. This compares to loss of $7.20 per share a year ago.

Zacks Investment Research (May 14, 2025)
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.

Benzinga (March 31, 2025)
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease and Skysona for cerebral adrenoleukodystrophy.

CNBC (February 21, 2025)
FDA greenlights first gene-editing treatment, Casgevy, for sickle cell disease

CNBC's Angelica Peebles reports on the latest news in bioscience.

CNBC Television (December 8, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free